ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Tightening the gradient: ten years of dosimetric refinement in head and neck reirradiation.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to quantify changes in plan quality for head and neck reirradiation (reRT) on a constant C‑arm platform.
methodsThis retrospective study included 775 patients treated on a TrueBeam STx (Varian Medical Systems, Palo Alto, USA) between 2015 and 2025. Delivery transitioned from fixed-field IMRT during 2015-2019 to VMAT during 2020-2025. Planning was performed in Eclipse, with one upgrade from version 11.0.31 to 15.6.06. Endpoints included PTV D95, D98, D50, D2; different gradient indices; and doses to the spinal cord, brainstem, carotids, mandible, oral cavity, and DARS. Year-wise differences were tested using ANOVA with Bonferroni-adjusted pairwise comparisons and nonparametric sensitivity analyses. Linear models included calendar year and the log-transformed PTV volume.
resultsMean PTV D95 increased from 96.4 ± 0.5% to 99.6 ± 0.2%, while D2 decreased from 108.5 ± 1.6% to 104.0 ± 0.1%. Gradient indices decreased over the study period, indicating reduced dose spillage and steeper dose fall-off. Spinal cord and brainstem doses also declined substantially, with additional reductions in oral cavity and DARS doses. All four primary target endpoints showed significant year effects after multiplicity adjustment and nonparametric sensitivity testing. The PTV volume decreased from 700.2 ± 16.7 cc to 250.4 ± 14.7 cc, representing an approximately 64% reduction, and likely contributed to the observed improvements in gradient indices and OAR sparing. Temporal associations persisted after adjustment for the log-transformed PTV volume.
conclusionDosimetric outcomes improved over the study period, but these changes coincided with reduced target volume, treatment technique transition, TPS upgrade, and workflow maturation. The findings should be interpreted as multifactorial rather than as evidence of an isolated technological effect.
Indexed as
Identifiers
42841928What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.